SYMPOSIUM III, June 14, 2017: Biomarkers and lung cancer

KENNETH EMANCIPATOR, MD, DABP
Executive Medical Director & Head of Companion Diagnostics Translational Medicine
Physician, in vitro companion diagnostic device expert, Merck, Kenilworth, NJ, USA

Kenneth Emancipator, MD, DABP is a renowned pathologist who is the Executive Medical Director and Head of Companion Diagnostics for Merck & Company. He led the Merck team which partnered with Agilent Technologies (Dako) to develop the first FDA-approved companion diagnostic in cancer immunotherapy, the 22C3 PD-L1 immunohistochemistry test, which later enabled Keytruda® (pembrolizumab) to become the first immunotherapy to be approved for first-line treatment of non-small cell lung cancer. Dr. Emancipator was one of six members of the Keytruda Team to receive the 2015 PhRMA Research and Hope Award for Biopharmaceutical Industry Research on behalf of Merck.

Dr. Emancipator's primary interest has always been the role of diagnostic tests in driving clinical decisions. His current focus is personalized medicine, with a special emphasis on precision immuno-oncology. He has in-depth experience with *in vitro* diagnostics from every perspective, having served as medical director both for academic clinical laboratories and for diagnostics manufacturers, and having been a reviewer for the US Food and Drug Administration, before joining the pharmaceutical industry.

Dr. Emancipator received his A.B. degree from Harvard University and his MD from St. Louis University. He completed his medical internship at Westchester County Medical Center and his pathology residency at the State University of New York at Stony Brook. He has held appointments at the US National Institutes of Health, the US Food and Drug Administration, Cornell University, Beth Israel Medical Center, Bayer Healthcare, Siemens Healthcare, and Abbott Molecular prior to joining Merck. He also has held various leadership positions with the American Society for Clinical Pathology (ASCP), including chairing its Council on Clinical Chemistry, serving on its Board of Certification, serving on its Finance Committee, and eventually being elected Treasurer and to the Board of Directors. He continues to serve as a reviewer for ASCP's *American Journal of Clinical Pathology*.

Dr. Emancipator has authored over 100 publications and has presented at more than 100 extramural programs. When not in his office at Merck, he is most likely to be found along the beaches and coastal waterways of Eastern Long Island.

RUI MANUEL REIS, PHD,
Coordinator, Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, S. Paulo, Brazil

Dr. Rui Manuel Reis has been involved in Cancer Research since 1996, where at IPATIMUP/Porto/Portugal, under the supervision of Prof. Sobrinho Simões, worked on thyroid cancer genetic instability. In 1998 He started his PhD at IARC/Lyon/France on molecular pathology of brain tumors, under the supervision of Prof. Paul Kleihues. In 2002, he did a Post-doc at the VUMC/Amsterdam/The Netherlands, in collaboration with IPATIMUP, under the supervision of Prof. Gerrit Meijer and Fátima Carneiro, on chromosomal aberrations of gastric tumors by microarray-CGH. In 2003 he was appointed Assistant Professor of Human Genetics at the Medical Faculty, University of Minho, Braga, Portugal. In 2010, he moved to Barretos Cancer Hospital/Brazil to implement and coordinate its Research Center and Molecular Diagnostic Laboratory. His expertise is in cancer biomarkers across distinct tumor types, and applying different methodologies, from gene mutations, copy number aberrations to gene expression alterations. He is well prepared for implementation of new methodologies and research groups in cancer research. During his post-doc he implemented microarray CGH at VUMC, and at Minho University, Portugal I initiate a new Oncobiology research group at a new medical faculty, and later at Barretos Cancer Hospital, he established and now coordinate a cancer research center and diagnostic laboratory that currently has more than 100 members. He also has extensive experience in international collaborations: COST - European Cooperation in the field of Scientific and Technological Research, "Molecular cytogenetics of solid tumors," 2004-2006; Marie Curie Conferences: "Genome Architecture in Relation to Disease," Amsterdam/Helsinki/Madrid/Braga/Edinburgh, 2006-2009; SIOP (Société International d'Oncologie Pédiatrique), Brain Tumor Committee, High Grade Glioma WG, 2009-2012; IMMENSE (International Multiple Myeloma rESEarch) consortium, 2010-present; member and local coordinator of NCI-LACRN (U.S. – Latin America Cancer Research Network); Steering Committee of ICGC (International Cancer Genome Consortium), 2013- present; and WIN (World Innovative Networking), 2013-present.